Canaccord Genuity raised its rating on Cyberonics CYBX from Hold to Buy and increased its price target from $34 to $56.
Canaccord Genuity said, "We are upgrading Cyberonics to BUY from Hold as our previous concerns about the impact of a competitive drug entering the market and a slowdown in replacement sales have not played out to our pessimistic expectations. Furthermore, the company continues to execute from both a sales and product development standpoint. Lastly we believe a change in reimbursement to coverage for treatment- resistant depression by CMS could provide significant upside to expectations and the stock price."
Cyberonics closed at $46.36 on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in